Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 6Hematologic Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Parathyroid Neoplasms 2Otorhinolaryngologic Neoplasms 2Osteosarcoma 2Neoplasms 2Multiple Myeloma 2Mixed Tumor, Mesodermal 2Mesothelioma, Cystic 2Mesothelioma 2Lymphoma, T-Cell 2Lymphoma 2Liposarcoma 2Leiomyosarcoma 2Kidney Neoplasms 2Hemangiosarcoma 2Head and Neck Neoplasms 2Fibrosarcoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Chondrosarcoma 2Carcinoma, Small Cell 2Breast Neoplasms 2Adenosarcoma 2

Interventions

Brentuximab Vedotin 16ceritinib 3Rifampin 3brigatinib 2Vincristine 2Prednisone 2Gemcitabine 2Doxorubicin 2Cyclophosphamide 2Crizotinib 210-propargyl-10-deazaaminopterin 2tislelizumab 1repotrectinib 1relatlimab 1ontuxizumab 1iratumumab 1entrectinib 1brincidofovir 1belinostat 1alectinib 1XMAB-2513 1WW Domain-Containing Oxidoreductase 1Vitamin B 12 1Suspensions 1Nivolumab 1Midazolam 1MLN 8237 1Ketoconazole 1Itraconazole 1Folic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large-Cell, Anaplastic × belinostat × Clear all
NCT06561048 2026-04-08

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals, Inc.

Phase 3 Recruiting
150 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡